NCT01942083: A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma) |
|
|
| Terminated | 1 | 33 | RoW | OPB-111077 | Korea Otsuka Pharmaceutical Co., Ltd. | Advanced Hepatocellular Carcinoma | 06/16 | 07/16 | | |
